Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Langley

Vascular Surgery Amarillo, TX Medical Doctor

NPI 1447236690 CMS profile 201621

1000 S Coulter St Ste 20, Amarillo, TX 79106

Open in the dashboard

General payments

$7,352

102 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Langley of Amarillo, TX is reported in the CMS Open Payments database as having received $7,352 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $946 8
2024 General $615 18
2023 General $941 12
2022 General $391 11
2021 General $529 21
2020 General $256 4
2019 General $3,675 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Langley
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to David Langley were reported at $946. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year David Langley Vascular Surgery median Middle half National median
2019 $3,675 $796 $226–$2,363 $163
2020 $256 $348 $118–$1,110 $114
2021 $529 $471 $158–$1,421 $132
2022 $391 $725 $222–$2,183 $149
2023 $941 $836 $257–$2,440 $160
2024 $615 $909 $252–$2,619 $164
2025 $946 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ge Healthcare $1,862 1 payment
  2. Endologix, Inc. $1,540 5 payments
  3. Siemens Medical Solutions USA, Inc. $895 8 payments
  4. Silk Road Medical, Inc. $688 16 payments
  5. W. L. Gore & Associates, Inc. $649 5 payments
  6. Boston Scientific Corporation $385 11 payments
  7. Janssen Pharmaceuticals, Inc $286 15 payments
  8. Medtronic, Inc. $149 7 payments
  9. CVRx, Inc. $135 1 payment
  10. Smith+Nephew, Inc. $103 5 payments
  11. Other $661 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,784 97 payments
  2. Travel and Lodging $2,568 5 payments
Products named General payments · program years 2019–2025
  1. Artis pheno $895 8 payments
  2. Alto Abdominal Stent Graft System $830 2 payments
  3. ENROUTE Transcarotid Stent $508 14 payments
  4. ENROUTE Transcarotid Neuroprotection System $508 14 payments
  5. Ovation $440 2 payments
  6. AFX $440 2 payments
  7. XARELTO $286 15 payments
  8. ENDOCROSS Device $270 1 payment
  9. Torus Stent Graft System $270 1 payment
  10. GORE TAG Thoracic Endoprosthesis $247 1 payment
  11. Other $3,221 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

520

Median for Interventional Radiology: 38

Drug cost

$43,839

Median for Interventional Radiology: $333

Branded share of claims

50.2%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 33 $23,110
Xarelto Rivaroxaban Brand 21 $16,337
Cilostazol Generic 149 $2,371
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 99 $724
Clopidogrel Clopidogrel Bisulfate Brand 108 $626
Pantoprazole Sodium Generic 18 $197
Gabapentin Generic 26 $173
Tramadol Hcl Generic 34 $113
Mupirocin Generic 12 $98
Ondansetron Hcl Generic 20 $91

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 146 billing codes

Paid by Medicare

$180,601

Medicare's payments for the services billed

Medicare patients

834

Average age 75

Services billed

1,562

378 women, 456 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 54%
Diabetes 42%
Chronic kidney disease 40%
Heart failure 34%
COPD 31%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record